Abstract: Objective To prompt the clinical to pay high attention to chemotherapy in patients with non-Hodgkin's lymphoma risk. MethodsThe clinical pharmacists assessed a recurrence and refractory non-Hodgkin's lymphoma patient during chemotherapy, with the potential risks of tumor dissolve syndrome,activation of hepatitis B virus, bone marrow inhibition, thrombosis, delayed diarrhea, acute and late-occurred vomiting evaluation,and implementation of pharmaceutical care. ResultsThe patient finished this cycle treatment with no serious adverse reactions during chemotherapy. ConclusionThe clinical professionals should be aware of the risks in the process of chemotherapy for non-Hodgkin lymphoma patients and improve the chemotherapy drug safety.

Key words: clinical pharmacist, non-Hodgkin lymphoma, assess, pharmaceutical care